188 related articles for article (PubMed ID: 34924273)
1. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study.
Kuo CJ; Le PH; Tai WC; Wu KL; Yen HH; Yen CW; Tung SY; Chung CS; Su MY; Chiu CT
J Formos Med Assoc; 2022 Sep; 121(9):1689-1695. PubMed ID: 34924273
[TBL] [Abstract][Full Text] [Related]
2. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
[TBL] [Abstract][Full Text] [Related]
3. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study.
Meng RP; Huang BB; Wei YL; Lyu L; Yang H; Liu C; Zhou HL; Liao XP; Zhou JY; Xie X
J Dig Dis; 2024 Apr; 25(4):230-237. PubMed ID: 38764418
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis.
Sablich R; Urbano MT; Scarpa M; Scognamiglio F; Paviotti A; Savarino E
Sci Rep; 2023 Feb; 13(1):1816. PubMed ID: 36725872
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan.
Yokoyama K; Yamamoto Y; Nambu R; Hagiwara SI; Abukawa D; Mizuochi T; Kudo T; Sado T; Iwata N; Ishige T; Iwama I; Kumagai H; Arai K; Shimizu T
J Gastroenterol Hepatol; 2023 Jul; 38(7):1107-1115. PubMed ID: 37278369
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis.
Kakiuchi T; Yoshiura M
Clin Ther; 2022 Jul; 44(7):1028-1032. PubMed ID: 35779956
[TBL] [Abstract][Full Text] [Related]
13. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
14. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study.
Lin WC; Tai WC; Chang CH; Tu CH; Feng IC; Shieh MJ; Chung CS; Yen HH; Chou JW; Wong JM; Liu YH; Huang TY; Chuang CH; Tsai TJ; Chiang FF; Lu CY; Hsu WH; Yu FJ; Chao TH; Wu DC; Ho AS; Lin HH; Feng CL; Wu KL; Wong MW; Tung CC; Lin CC; Chen CC; Hu HM; Lu LS; Wang HS; Wu IC; Kuo HY; Wu JF; Yao Shih H; Ni YH; Tang SL; Chen PH; Wei SC
Inflamm Bowel Dis; 2023 Nov; 29(11):1730-1740. PubMed ID: 36626567
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L; Shmidt E; Hirten R; Faleck D; Parikh MP; Whitehead D; Boland BS; Singh S; Sagi SV; Fischer M; Chang S; Barocas M; Luo M; Lasch K; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Shen B; Kane S; Loftus EV; Siegel CA; Sands BE; Colombel JF; Sandborn WJ; Dulai PS
Am J Gastroenterol; 2018 Sep; 113(9):1345. PubMed ID: 29946178
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
Engel T; Ungar B; Yung DE; Ben-Horin S; Eliakim R; Kopylov U
J Crohns Colitis; 2018 Jan; 12(2):245-257. PubMed ID: 29077833
[TBL] [Abstract][Full Text] [Related]
19. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?
Rodríguez-Lago I; Benítez JM; Sempere L; Sáez-González E; Barreiro-de Acosta M; de Zárate JO; Cabriada JL
J Clin Apher; 2019 Dec; 34(6):680-685. PubMed ID: 31518013
[TBL] [Abstract][Full Text] [Related]
20. A metabolomics-driven model for early remission prediction following vedolizumab treatment in patients with moderate-to-severe active ulcerative colitis.
Jiang L; Liu X; Su Y; Chen Y; Yang S; Ke X; Yao K; Guo Z
Int Immunopharmacol; 2024 Feb; 128():111527. PubMed ID: 38215655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]